Cannabis Law Report

SEPTEMBER 4, 2021

Much of the argument, before Circuit Judges Mark Bennett, Sandra Ikuta and Ryan Nelson, focused on whether the DEA’s conclusion that it could not waive any part of the federal Controlled Substances Act (CSA), which bans psilocybin except for limited research purposes, could even be appealed. Forty-one states have passed such laws.

Clinical Trials 109

Clinical Trials Law DEA Patients 109

Cannabis Law Report

OCTOBER 15, 2021

The Drug Enforcement Administration (DEA) is proposing a dramatic increase in the legal production of marijuana and psychedelics like psilocybin, LSD, MDMA and DMT to be used in research next year. Imagine reading that headline in 1980! Marijuana Moment report.

DEA 96

DEA Clinical Trials Extraction Marijuana 96

Cannabis Law Report

JUNE 3, 2021

A Seattle palliative care physician has filed a lawsuit against the DEA, contesting its decision to ban psilocybin for use by terminally ill patients.

DEA 98

DEA Access Clinical Trials Patients 98

Veriheal

JUNE 29, 2021

In order to legally access other therapies including nature-based options such as psilocybin , you must gain access under a Right to Try law which requires you to have a terminal condition. Today there are 41 states that have enacted some form of a Right to Try or RTT laws. Patients Are Not In This Alone.

Therapy 64

Therapy DEA Patients Clinical Trials 64

Cannabis Law Report

JULY 9, 2021

The state of the law on psychedelic substances is in flux. Some of the most promising substances, and the law applicable to each, are outlined below: Psilocybin. As such, the use, sale, and possession of psilocybin in the United States is illegal under federal law. have also passed “Right to Try” laws.

Law 81

Law Therapy Clinical Trials Research and Development 81

Cannabis Law Report

MARCH 30, 2022

Senate Bill 253: The Cannabidiol and Marihuana Research Expansion Act provides the office of US Attorney General, rather than the US Drug Enforcement Administration, the discretion to license scientists to engage in clinical trials involving the use of cannabis by human subjects. The full text of S. 253 is online here.

Legislation 95

Legislation Clinical Trials DEA Access 95

Cannabis Law Report

NOVEMBER 4, 2021

Drug Enforcement Agency (DEA) to cultivate marijuana for research purposes. The DEA dragged their feet on this plan for years, so lawsuits were filed. Litigation against the DEA and Department of Justice that Matthew Zorn and I brought on behalf of Dr. Since then, the DEA has licensed four additional bulk manufacturers of marijuana.

DEA 52

DEA Clinical Trials Advocacy Legislation 52

Cannabis Law Report

NOVEMBER 22, 2019

MMJ International Holdings, the premier medical cannabis research company, announced that it has received DEA approval to ship THC and CBD from Canada. ”We are pleased with the DEA ‘s cooperation and support to facilitate our company mission to service the unmet needs of patients suffering from these chronic diseases.”

DEA 51

DEA Clinical Trials THC Research and Development 51

Cannabis Law Report

APRIL 12, 2022

Attorneys representing a cannabis biopharma conglomerate and federal cannabis cultivation license applicant filed a petition in court today, citing that the Drug Enforcement Agency (DEA) is taking too long to issue a determination for its application. . Breaking Exclusive: Another Cannabis Company Sues the DEA. Read more at.

DEA 52

DEA Cultivation Clinical Trials Cannabis 52

NewsMunchies

NOVEMBER 12, 2021

In clinical trials, psilocybin (the psychoactive substance in mushrooms) has shown tremendous promise in treating severe depression, post-traumatic stress disorder, and other mental illnesses. The War on Drugs is a failure and continuing to focus law enforcement resources on people using cannabis and psilocybin doesn’t make sense.

Clinical Trials 90

Clinical Trials Therapy Decriminalization DEA 90

CannaMD

NOVEMBER 15, 2020

are even more frustrated, describing the mechanisms for cannabis research as “broken” with a “ridiculous set of laws” that have prevented good and timely research. federal law, cannabis is still classified as a Schedule I drug, the most restrictive classification. The DEA would then be the exclusive distributor.

DEA 105

DEA Clinical Trials Cannabinoids Treatment 105

Canna Law Blog

MARCH 4, 2020

Similar to ketamine, psilocybin has shown great promise in clinical trials for helping to effectively treat depression and PTSD (and we’ve written about psilocybin several times on this blog, including here and here ). This post is dedicated to clearing up some of the confusion behind ketamine clinic set-up and operation.

Therapy 102

Therapy Legalization Chronic Pain DEA 102

Veriheal

APRIL 11, 2022

federal law , it has not yet been used in any commonly prescribed medicines. The company initiated the first legal transfer (as deemed by federal law) to the U.S. Drug Enforcement Agency (DEA). federal law. federal law, from which point, informed choices can be made about the use of cannabis and cannabinoids.

Pharmaceutical 105

Pharmaceutical Research and Development DEA Clinical Trials 105

Cannabis Law Report

OCTOBER 4, 2021

In Attorney , Federal Law , Kathryn Tucker , Oregon , Psychedelics. A multitude of recent clinical trials shows the clear promise of psilocybin for this population suffering from these debilitating conditions. Access to Psilocybin Therapy Pursuant to Right to Try Laws. September 30, 2021. Kathryn Tucker.

Therapy 52

Therapy Patients Law Clinical Trials 52

CannaMD

AUGUST 8, 2020

Drugs, substances, and certain chemicals used to make drugs are classified into five categories (known as schedules ) depending on the Department of Drug Enforcement Agency (DEA)’s definition of the drug’s acceptable medical use and abuse/dependency potential. However, there are a number of restrictions. CBD Scheduling Rule Change.

CBD 105

CBD DEA Research and Development Hemp 105

Canna Law Blog

FEBRUARY 4, 2019

Thus, federal law effectively prohibits importation of marijuana into the United States. Drug Enforcement Administration (DEA) granted permission for a Canadian marijuana company (Tilray) to export medicinal cannabis to University of California San Diego for clinical trial. In September 2018, however, the U.S.

Clinical Trials 98

Clinical Trials Recreational Medicine DEA 98

Cannabis Law Report

FEBRUARY 10, 2022

Court of Appeals for the Ninth Circuit dismissed a petition for review of a Drug Enforcement Administration (DEA) response to an attorney’s letter seeking advice and guidance on how a physician could administer psilocybin to a terminally ill patient without incurring liability under the Controlled Substances Act (CSA). By Allison Campbell.

DEA 52

DEA Clinical Trials Policy Research and Development 52

Cannabis Law Report

OCTOBER 20, 2021

Bank of America (BoA) is reportedly terminating its banking relationship with Scottsdale Research Institute (SRI), a DEA-registered facility that carries out important marijuana research. The quality of this cannabis had been criticised by a number of researchers, including Dr. Sisley.

Banking 52

Banking Clinical Trials DEA History 52

Cannabis Law Report

MAY 31, 2022

The only psychedelic drug that is approved (outside of clinical trials) for psychiatric use—as opposed to anesthesia—through the traditional medical system is Ketamine. How will the federal government react to another new industry that operates in clear violation of the federal black letter law? On March 5, 2019, the U.S.

Clinical Trials 52

Clinical Trials Legalization Therapy Decriminalization 52

Cannabis Law Report

MARCH 18, 2022

Many of these drugs are regulated by a patchwork of state and federal laws regulating Schedule I controlled substances. The establishment of the firm’s Psychedelics and Emerging Therapies team makes Husch Blackwell the first Am Law 100 firm to create a practice devoted to serving the psychedelics industry.

Therapy 52

Therapy Research and Development Clinical Trials Environment 52

Cannabis Law Report

JANUARY 11, 2019

federal law protects the retail sale of hemp-derived CBD. . Our analysis follows: Hemp-derived CBD is no longer a controlled substance under federal law. The FDA’s position on CBD is unsettled and unsupported by law. While the DEA is now officially out of the hemp regulation business, the U.S.

Hemp 49

Hemp CBD Law Seed-To-Sale 49

Cannabis Law Report

APRIL 8, 2022

This year, we are completing the second Phase 3 clinical trial of MDMA-assisted therapy for PTSD , the final stage prior to requesting FDA approval for a new prescription treatment to help heal trauma. Later that year, Doblin sued the DEA for the first time. Rick Doblin, Ph.D., and Michael Mithoefer, M.D., Lyle Craker, Ph.D.,

Clinical Trials 52

Clinical Trials Therapy Research and Development DEA 52

Veriheal

AUGUST 31, 2020

However, social and economic barriers like racial stereotypes and lack of access to care centers have historically barred Hispanic community members from seeking medical cannabis and participating in clinical trials. Essay: “The Nature of Hemp and Law: Hazy Regulation”. Jack Devanna . School: The University of Rhode Island.

Research and Development 119

Research and Development Education Agriculture Patients 119

The Cannigma

MAY 6, 2021

Because most delta-8 products are derived from hemp plants, it is believed by some that they fall under a loophole in federal cannabis laws. The Drug Enforcement Administration (DEA) recently issued a clarification on the matter, stating that “All synthetically derived tetrahydrocannabinols remain schedule 1 controlled substances”.

THC 145

THC Cannabinoids Concentrates Hemp 145

Cannabis Law Report

APRIL 21, 2022

The availability of larger quantities of cGMP-compliant MDMA will facilitate ongoing clinical trials and provide for future therapeutic use following anticipated regulatory approvals. in each of the four validation trials with an acceptable yield, which is a noteworthy accomplishment.

Clinical Trials 52

Clinical Trials Research and Development Therapy Media 52

Cannabis Law Report

SEPTEMBER 20, 2019

The sale will greatly reduce the current and future burn rate of the company and allow it to focus on achieving profitability, seeking a DEA license, and implementing GMP, a set of regulations promulgated by the U.S. location.

Clinical Trials 40

Clinical Trials Research and Development DEA Business 40

Cannabis Law Report

OCTOBER 5, 2021

The drug has previously been used with some success in clinical trials designed to treat depression. These trials typically involve the use of music playlists to support the psychedelic experience.

Clinical Trials 52

Clinical Trials Research and Development DEA Therapy 52

Cannabis Law Report

MARCH 2, 2020

Any approved medicines will have to be rescheduled by the Drug Enforcement Administration (DEA). Back in 2018, the DEA rescheduled GW Pharmaceuticals ‘ (NASDAQ: GWPH) cannabis-based epilepsy medicine, Epidiolex, following its regulatory approval by the FDA. Fortunately, this issue shouldn’t be a show-stopper.

Medicine 59

Medicine Therapy DEA Pharmaceutical 59

Cannabis Law Report

APRIL 13, 2022

Complementary businesses combine to create a preeminent North American platform with operations spanning 13 wellness clinics, four research sites and one bioanalytical laboratory. Hosting clinical trials for MDMA ( MAPS Public Benefit Corporation), psilocybin (the Usona Institute), LSD (MindMed) and ketamine (the University of Utah ).

Clinical Trials 52

Clinical Trials Research and Development Therapy Treatment 52

Cannabis Law Report

DECEMBER 21, 2021

It was officially listed on the NYSE in August and granted a DEA schedule I manufacturing license in November. Within a few months, it had completed the first phase of its clinical trial of DMT in combination with supportive psychotherapy and commenced a phase 2a trial. Small Pharma (CVE: DMT ) (OTCMKTS: DMTTF ).

Clinical Trials 52

Clinical Trials Therapy Treatment DEA 52

Cannabis Law Report

AUGUST 18, 2022

With rapid change expected in state and federal laws and regulations governing the industry, we understood the urgency of launching a practice team that provides sophisticated legal counsel bolstered by deep knowledge of science and the pace of innovation.” However, change appears imminent.

Therapy 52

Therapy Research and Development Pharmaceutical Treatment 52

Cannabis Law Report

APRIL 1, 2019

It aims to turn the plants’ chemical compounds into 2,500 5-milliliter bottles – the size of a teaspoon – of cannabis oil and sublingual drops for clinical trials among volunteer patients as early as July. It remains to be seen whether the Drug Enforcement Authority, or DEA, will designate cannabis zones for these farmers.

Research and Development 40

Research and Development Pharmaceutical Clinical Trials DEA 40

Cannabis Law Report

JUNE 4, 2021

This has not yet been enforced or brought to a court of law and again I will make the analogy to beer and wine in the alcohol industry (equivalent to Delta-8) vs hard liquor (more equivalent to Delta-9). Delta-8 appears to us at Cannabis Law Report, the canary in the coal mine for new cannabis compounds.

Research and Development 105

Research and Development Seed-To-Sale Cannabinoids THC 105

SpeedWeed

MARCH 18, 2021

for the production of cannabis used in federally-regulated clinical trials. Wasn’t the DEA going to let others grow research-grade cannabis? Early on in the study, criticism over the poor quality and low potency of the NIDA-supplied cannabis prompted Johns Hopkins University to withdraw from the multi-year clinical trials.

Clinical Trials 40

Clinical Trials THC Strains Cannabis 40

SpeedWeed

MARCH 5, 2021

One, they have been determined by the US Food and Drug Administration to be clinically safe and effective treatments for a specific medical condition. Two, they are federally classified by DEA and HHS as Schedule II, III, IV or V substances. Rescheduling cannabis will not necessarily facilitate clinical research.

Business 52

Business Policy Clinical Trials Research and Development 52

Cannabis Law Report

JULY 12, 2019

Recent studies on the effectiveness of cannabidiol in the rare seizure disorders Dravet Syndrome and Lennox-Gastaut syndrome have prompted a biopharmaceutical company to perform clinical trials of its own to bring a cannabidiol based drug to the American market through the process of FDA approval. 32: United States DEA.

Extraction 73

Extraction Pharmaceutical CBD Epilepsy 73

Canna Law Blog

MAY 7, 2020

Ole Miss got the cannabis study and research cultivation gig from the DEA (via a contract with the National Institute on Drug Abuse (NIDA)) in 1968. for various studies, including FDA-approved clinical trials. In 2016, the DEA finally shifted to different treatment around expanded research efforts into cannabis beyond Ole Miss.

DEA 93

DEA Research and Development Cultivation Supply Chain 93